

For AML patients, **time is of the essence.** Get IDHNow for AML for informed treatment decisions

NeoGenomics and Servier have partnered to provide *IDH* testing for eligible AML patients.

Mutated *IDH1* is an oncogenic driver that occurs in up to 16% of AML cases and is an actionable target for treatment.¹ Clinical practice guidelines recommend performing molecular testing to identify *IDH* mutations in AML patients.² Expedited analysis of biomarkers in patients ineligible for intensive chemotherapy is crucial for informing treatment decisions and identifying new therapies that could improve patient outcomes.

This first step could lead to better outcomes for your patients.

NeoGenomics has partnered with Servier to provide IDHNow for AML, a sponsored testing program for eligible AML patients. Participating patients benefit from expedited *IDH1* profiling results, allowing you to make treatment decisions as quickly as possible for your patients.

Patients with newly diagnosed AML who do not have a known *IDH1* mutation, and who reside and receive treatment in the US and its territories may be eligible for the IDHNow for AML Sponsored Testing Program at no cost.



[NeoGenomics.com/IDHNOW_STP](https://neogenomics.com/IDHNOW_STP)

¹ Zarnegar-Lumley S, Alonzo TA, Gerbing RB, et al. Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis. *Blood Advances*. 2023;7(19):5941-5953. doi:10.1182/bloodadvances.2022008282
² Arber DA et al. *Arch Pathol Lab Med*. 2017;141(10):1342-1393. doi:10.5858/arpa.2016-0504-CP
 ©2024 NeoGenomics Laboratories, Inc. All rights reserved. All trademarks are the property of their respective owners.